Experienced in Tongue Cancer

Dr. Juneko E. Grilley-Olson

Hematology Oncology | Hematology | Oncology
Duke Health
Duke Health Integrated Practice Inc
2301 Erwin Rd, 
Durham, NC 
Accepting New Patients
Offers Telehealth
Experienced in Tongue Cancer
Duke Health
Duke Health Integrated Practice Inc
2301 Erwin Rd, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Juneko Grilley-Olson is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Grilley-Olson is rated as an Experienced provider by MediFind in the treatment of Tongue Cancer. Her top areas of expertise are Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Bone Tumor, and Fibrosarcoma. Dr. Grilley-Olson is currently accepting new patients.

Her clinical research consists of co-authoring 63 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

DUKE HEALTH INTEGRATED PRACTICE INC
2301 Erwin Rd, Durham, NC 27705
Call: 919-684-8111
Other Locations
DUKE HEALTH INTEGRATED PRACTICE INC
20 Duke Medicine Cir, Durham, NC 27710
Call: 919-684-8111
DUKE HEALTH INTEGRATED PRACTICE INC
2351 Erwin Rd, Durham, NC 27705
Call: 919-684-8111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drug: MDM2 Inhibitor KRT-232
Study Phase: Phase 1
Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN
Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug, Biological
Study Drugs: Cetuximab, PD 0332991
Study Phase: Phase 1/Phase 2
Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Enrollment Status: Completed
Publish Date: June 07, 2023
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, 5-Fluorouracil, Hydroxyurea, Paclitaxel, Veliparib
Study Phase: Phase 1/Phase 2
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: May 01, 2023
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drugs: Pazopanib, Pazopanib Hydrochloride, Sapanisertib
Study Phase: Phase 1/Phase 2
LCCC 1330 - A Phase II Study of Weekly Carboplatin, Paclitaxel and Cetuximab for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
LCCC 1330 - A Phase II Study of Weekly Carboplatin, Paclitaxel and Cetuximab for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Completed
Publish Date: August 12, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

63 Total Publications

ASO Visual Abstract: Circulating Tumor DNA (ctDNA) is Reliably Detected in Patients with Metastatic Malignant Phyllodes Tumors-a Feasibility Study.
ASO Visual Abstract: Circulating Tumor DNA (ctDNA) is Reliably Detected in Patients with Metastatic Malignant Phyllodes Tumors-a Feasibility Study.
Journal: Annals of surgical oncology
Published: August 18, 2025
View All 63 Publications
Similar Doctors
Advanced in Tongue Cancer
Dr. Jameel M. Muzaffar
Hematology Oncology | Hematology | Oncology
Advanced in Tongue Cancer
Dr. Jameel M. Muzaffar
Hematology Oncology | Hematology | Oncology

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (0.2 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jameel Muzaffar is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Muzaffar is rated as a Distinguished provider by MediFind in the treatment of Tongue Cancer. His top areas of expertise are Adenoid Cystic Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Epithelial-Myoepithelial Carcinoma, Mastoidectomy, and Septoplasty. Dr. Muzaffar is currently accepting new patients.

Experienced in Tongue Cancer
Dr. Mark L. Graham
Hematology Oncology | Hematology | Oncology
Experienced in Tongue Cancer
Dr. Mark L. Graham
Hematology Oncology | Hematology | Oncology

Wakemed Specialists Group LLC

210 Ashville Ave, 
Cary, NC 
 (20.3 miles away)
919-350-2800
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Graham is a Hematologist Oncology specialist and a Hematologist in Cary, North Carolina. Dr. Graham is rated as a Distinguished provider by MediFind in the treatment of Tongue Cancer. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Angiosarcoma, Bone Marrow Aspiration, and Endoscopy. Dr. Graham is currently accepting new patients.

Experienced in Tongue Cancer
Dr. Jared M. Weiss
Hematology Oncology | Hematology | Oncology
Experienced in Tongue Cancer
Dr. Jared M. Weiss
Hematology Oncology | Hematology | Oncology

University Of North Carolina At Chapel Hill

2801 Blue Ridge Rd, 
Raleigh, NC 
 (18.3 miles away)
984-974-0500
Languages Spoken:
English, French, Italian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jared Weiss is a Hematologist Oncology specialist and a Hematologist in Raleigh, North Carolina. Dr. Weiss is rated as a Distinguished provider by MediFind in the treatment of Tongue Cancer. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Squamous Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Weiss is currently accepting new patients.

VIEW MORE TONGUE CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Grilley-Olson's expertise for a condition
ConditionClose
    • Distinguished
    • Adult Soft Tissue Sarcoma
      Dr. Grilley-Olson is
      Distinguished
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Alveolar Soft Part Sarcoma
      Dr. Grilley-Olson is
      Distinguished
      . Learn about Alveolar Soft Part Sarcoma.
      See more Alveolar Soft Part Sarcoma experts
    • Angiosarcoma of the Scalp
      Dr. Grilley-Olson is
      Distinguished
      . Learn about Angiosarcoma of the Scalp.
      See more Angiosarcoma of the Scalp experts
    • Bone Tumor
      Dr. Grilley-Olson is
      Distinguished
      . Learn about Bone Tumor.
      See more Bone Tumor experts
    • Epithelioid Sarcoma
      Dr. Grilley-Olson is
      Distinguished
      . Learn about Epithelioid Sarcoma.
      See more Epithelioid Sarcoma experts
    • Fibrosarcoma
      Dr. Grilley-Olson is
      Distinguished
      . Learn about Fibrosarcoma.
      See more Fibrosarcoma experts
    View All 12 Distinguished Conditions
    • Advanced
    • Angiosarcoma
      Dr. Grilley-Olson is
      Advanced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Angiosarcoma of the Liver
      Dr. Grilley-Olson is
      Advanced
      . Learn about Angiosarcoma of the Liver.
      See more Angiosarcoma of the Liver experts
    • Chondrosarcoma
      Dr. Grilley-Olson is
      Advanced
      . Learn about Chondrosarcoma.
      See more Chondrosarcoma experts
    • Epithelial-Myoepithelial Carcinoma
      Dr. Grilley-Olson is
      Advanced
      . Learn about Epithelial-Myoepithelial Carcinoma.
      See more Epithelial-Myoepithelial Carcinoma experts
    • Ewing Sarcoma
      Dr. Grilley-Olson is
      Advanced
      . Learn about Ewing Sarcoma.
      See more Ewing Sarcoma experts
    • Ganglioneuroblastoma
      Dr. Grilley-Olson is
      Advanced
      . Learn about Ganglioneuroblastoma.
      See more Ganglioneuroblastoma experts
    View All 13 Advanced Conditions
    • Experienced
    • Acinic Cell Carcinoma of Salivary Glands
      Dr. Grilley-Olson is
      Experienced
      . Learn about Acinic Cell Carcinoma of Salivary Glands.
      See more Acinic Cell Carcinoma of Salivary Glands experts
    • Adrenal Cancer
      Dr. Grilley-Olson is
      Experienced
      . Learn about Adrenal Cancer.
      See more Adrenal Cancer experts
    • Agranulocytosis
      Dr. Grilley-Olson is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Grilley-Olson is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Breast Cancer
      Dr. Grilley-Olson is
      Experienced
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Colorectal Cancer
      Dr. Grilley-Olson is
      Experienced
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    View All 36 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.